FDA approves first RSV vaccine, for adults 60 and older
The Food and Drug Administration on May 3 approved the first U.S. vaccine for respiratory syncytial virus, Arexvy by GlaxoSmithKline Biologicals, for use in individuals aged 60 and older.
“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.”
Related News Articles
Perspective
While Congress passed legislation last month to fund the federal government through September, it’s looking like there will be very few other pieces of…
Headline
The Centers for Medicare & Medicaid Services Feb. 8 released a proposed rule intended to strengthen oversight of organizations that accredit health care…
Headline
The Department of Health and Human Services’ Office for Civil Rights Jan. 25 released guidance reminding hospitals, critical access hospitals and long-term…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 released an interim final rule implementing new enforcement authorities the agency will use if states…
Headline
The Food and Drug Administration Sept. 29 released a proposed rule that would phase out over four years its general enforcement discretion approach for most…
News
As proposed yesterday by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention recommends that starting this fall…